(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors

(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors

Gastrointestinal Stromal Tumor

Active, not recruiting

1

Start Date 08/01/2015

Age of Trial (yrs) 8.7

Gleevec-resistant

KIT/PDGFRA inhibitor + D842V inhibitor

Block KIT/PDGFRA

Specifically GIST and only GIST

BLU-285-1101 NAVIGATOR

Blueprint Medicines Corporation

Blueprint Medicines 617-714-6707 studydirector@blueprintmedicines.com

Oral

This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of BLU-285, administered orally (PO), in adult patients with unresectable GIST or other relapsed or refractory solid tumors. The study consists of 2 parts, a dose-escalation part (Part 1) and an expansion part (Part 2).